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AHFS American Hospital Formulary Service
ASHP American Society of Health-System Pharmacists (formerly, American Society  
     of Hospital Pharmacy)
BCG Bacillus Calmette–Guérin
BSC Biological safety cabinet
CACI Compounding aseptic containment isolator
CFR Code of Federal Regulations
CSTD Closed system drug-transfer device
DPI Drug package insert
EPA Environmental Protection Agency
FDA Food and Drug Administration
HEPA High-efficiency particulate air
HIPEC Heated intraperitoneal chemotherapy
IARC International Agency for Research on Cancer
IV Intravenous
MRHD Maximum Recommended Human Dose
MSHG Manufacturer’s safe handling guidance
NIOSH National Institute for Occupational Safety and Health
OEL Occupational exposure limit
OSHA Occupational Safety and Health Administration
ONS Oncology Nursing Society
PPE Personal protective equipment
SC Subcutaneous
SDS Safety Data Sheet (formerly Material Safety Data Sheet)
USP United States Pharmacopeial Convention
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Preamble: The National Institute for Occupational Safety and Health (NIOSH) Alert: Pre-
venting Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Healthcare 
Settings was published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/). In 
Appendix A of the Alert, NIOSH identified a sample list of hazardous drugs. The list was 
compiled from information provided by four institutions that had generated lists of haz-
ardous drugs for their respective institutions, as well as a list from the Pharmaceutical Re-
search and Manufacturers of America (PhRMA). The 2004 list was updated in 2010, 2012, 
and 2014. The current update (2016) adds 34 drugs, five of which have safe-handling rec-
ommendations from the manufacturers. In 2014, a new format was developed for the list of 
hazardous drugs, as described below. The review process for the addition of the new listings 
is described in the Federal Register: http://www.cdc.gov/niosh/docket/review/docket233a/
pdfs/233a_2015-12857.pdf. 
Drugs Considered Hazardous
I.  General Approach to Handling 
Hazardous Drugs
Early concerns about occupational exposure to 
antineoplastic drugs first appeared in the 1970s. 
Although the antineoplastic drugs remain the 
principal focus of the Alert, other drugs may also 
be considered hazardous because they are potent 
(small quantities produce a physiological effect) or 
cause irreversible effects. As the use and number 
of these potent drugs increase, so do opportuni-
ties for hazardous exposures among healthcare 
workers. For example, antineoplastic drugs such as 
cyclophosphamide and methotrexate have proved 
beneficial for treating nonmalignant diseases such 
as rheumatoid arthritis and multiple sclerosis. 
In the Alert (NIOSH 2004) and updates to the haz-
ardous drug list (NIOSH 2010 and 2012), NIOSH 
had previously recommended standard precau-
tions (universal precautions) be taken in handling 
hazardous drugs. Given the addition of new drug 
formulations and drugs in tablet and/or capsule 
form to the list, no single approach can cover the 
diverse potential occupational exposures to the 
drugs. All listed drugs are considered hazardous, 
but safe-handling precautions can vary with the 
activity and the formulation of the drug. Table 5 
provides some guidance on engineering controls 
and personal protective equipment (PPE) that ap-
plies to all listed drugs. The current NIOSH ap-
proach involves three groups of drugs: 
  Group 1: Antineoplastic drugs (AHFS Classifi-
cation 10:00) [ASHP/AHFS DI 2016]. Note that 
many of these drugs may also pose a reproduc-
tive risk for susceptible populations (Table 1). 
  Group 2: Non-antineoplastic drugs that meet 
one or more of the NIOSH criteria for a haz-
ardous drug. Note that some of these drugs may 
also pose a reproductive risk for susceptible 
populations (Table 2). 
  Group 3: Drugs that primarily pose a reproduc-
tive risk to men and women who are actively 
trying to conceive and women who are preg-
nant or breast feeding, because some of these 
drugs may be present in breast milk (Table 3). 
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All hazardous drugs, regardless of the formula-
tion, should be labeled as such to prevent improper 
handling. The majority of the reproductive risks as-
sociated with the drugs listed in Table 3 apply to 
women, but some can apply to men only (such as 
reduced fertility or sperm count) or to both men 
and women. Although all hazardous drugs should 
be handled according to recommended proce-
dures, especially if they must be prepared asepti-
cally, some populations of workers may not be at 
reproductive risk from handling drugs in Group 3. 
These include workers who are excluded from the 
susceptible populations for specific reasons such as 
age or infertility. In addition, drugs for which the 
manufacturer includes safe-handling guidance in 
the DPI are indicated. NIOSH carries out a haz-
ard identification on each drug on the basis of the 
NIOSH criteria for a hazardous drug. No attempt 
has been made to perform risk assessments on 
each drug or to propose exposure limits. NIOSH 
has provided guidance for personal protective 
equipment and ventilated engineering controls for 
some of the various scenarios in which a drug may 
be handled in healthcare settings (Table 5). This 
guidance does not cover all possible situations but 
provides general recommendations for the typical 
handling situations in healthcare.
With the increased availability of oral antineoplastic 
and other hazardous drugs, additional precautions 
are required in order to prevent worker exposure to 
these formulations. Some drugs defined as hazard-
ous may not pose a significant risk of direct occu-
pational exposure because of their dosage formula-
tion (for example, coated tablets or capsules—solid, 
intact medications that are administered to patients 
without modification of the formulation). However, 
they may pose a risk if the formulations are altered, 
such as by crushing tablets or making solutions 
from them outside a ventilated cabinet [Simmons 
2010; Goodin et al. 2011]. Uncoated tablets may 
present a risk of exposure from dust by skin con-
tact and/or inhalation when the tablets are counted 
[Shahsavarani et al. 1993; Ahmad et al. 2014]. Tablet 
and capsule forms of hazardous drugs should not 
be placed in automated counting machines, which 
subject them to stress and may introduce powdered 
contaminants into the work area [Fent et al. 2014]. 
Counting and pouring of hazardous drugs should 
be done carefully, and clean equipment should be 
dedicated for use with these drugs. Crushing tablets 
or opening capsules should be avoided and liquid 
formulations should be used whenever possible. 
During the compounding of hazardous drugs (e.g., 
crushing, dissolving, or preparing a solution or an 
ointment), workers should wear nonpermeable 
gowns and double gloves (Table 5). Guidelines for 
the safe compounding, administration, and dispos-
al of hazardous drugs have been developed by sev-
eral organizations [NIOSH 2004; ASHP 2006; ONS 
2011; USP 2016, OSHA 2016]. However, the lack of 
proper training for handling antineoplastic drugs 
in other specialty areas may be an issue that needs 
to be addressed [Abel 2000; Polovich and Giesker 
2011; Menonna-Quinn et al. 2013].
II. Defining Hazardous Drugs
Hazardous drugs include those used for cancer che-
motherapy, antiviral drugs, hormones, some bio-
engineered drugs, and other miscellaneous drugs. 
The NIOSH definition of hazardous drugs used in 
the Alert is based on a definition originally devel-
oped in 1990 by the American Society of Hospital 
Pharmacists [ASHP 1990], currently known as the 
American Society of Health-System Pharmacists. 
Thus, the NIOSH definition may not accurately in-
dicate the potential toxicity criteria associated with 
some of the newer-generation pharmaceuticals 
used in healthcare. For example, bioengineered 
drugs target specific sites in the body, and although 
they may or may not pose a risk to healthcare work-
ers, some may pose a risk to patients.
NIOSH and other organizations are still gather-
ing data on the potential toxicity and health effects 
related to highly potent drugs and bioengineered 
drugs. Therefore, when working with any hazard-
ous drug, healthcare workers should follow the 
approaches described in Table 5, along with any 
recommendations included in the manufacturer’s 
Safety Data Sheet (SDS) or the drug package inserts 
(DPIs).
A. ASHP Definition of Hazardous Drugs
ASHP defines hazardous drugs in its 1990 revision 
of the Technical Assistance Bulletin on Handling 
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Hazardous Drugs* [ASHP 1990]. The bulletin gives 
criteria for identifying potentially hazardous drugs 
that should be handled in accordance with an es-
tablished safety program [ASHP 2006; Massoomi 
et al. 2008; Eisenberg 2009; ONS 2011]. The crite-
ria are prioritized to reflect the hierarchy of poten-
tial toxicity described below. Since the hazardous 
drugs covered by the Alert were designed as thera-
peutic agents for humans, human toxicity profiles 
should be given more weight than data from ani-
mal models or in vitro systems. Additional guid-
ance for defining hazardous drugs is available from 
the following sources: carcinogenicity [61 Fed 
Register 17960–18011 (1996b); IARC 2014], tera-
togenicity [56 Fed Register 63798–63826 (1991)], 
developmental toxicity [56 Fed Register 63798–
63826 (1991)], and reproductive toxicity [61 Fed 
Register 56274–56322 (1996a)]. 
B. NIOSH Revision of ASHP Definition
1. The 1990 ASHP definition of hazardous 
drugs was revised by the NIOSH Working 
Group on Hazardous Drugs for the Alert. 
Drugs considered hazardous include those 
that exhibit one or more of the following six 
characteristics in humans or animals: 
  Carcinogenicity 
  Teratogenicity or other developmental 
toxicity†
*ASHP [1990] definition of hazardous drugs:
1. Genotoxicity (i.e., mutagenicity and clastogenicity in 
short-term test systems)
2. Carcinogenicity in animal models, in the patient 
population, or both, as reported by the International 
Agency for Research on Cancer (IARC)
3. Teratogenicity or fertility impairment in animal studies 
or in treated patients
4. Evidence of serious organ or other toxicity at low doses 
in animal models or treated patients.
†All drugs have toxic side effects, but some exhibit toxicity at 
low doses. The level of toxicity reflects a continuum from 
relatively nontoxic to production of toxic effects in patients 
at low doses (for example, a few milligrams or less). For 
example, a daily therapeutic dose of 10 mg/day or a dose of 
1 mg/ kg per day in laboratory animals that produces serious 
organ toxicity, developmental toxicity, or reproductive tox-
icity has been used by the pharmaceutical industry to devel-
op occupational exposure limits (OELs) of less than 10 µg/
m3 after applying appropriate uncertainty factors [Sargent 
  Reproductive toxicity†
  Organ toxicity at low doses†
  Genotoxicity‡
  Structure and toxicity profiles of new 
drugs that mimic existing drugs deter-
mined hazardous by the above criteria
2. Determining Whether a Drug is Hazardous
Many hazardous drugs used to treat cancer (for ex-
ample, alkylating agents) bind to or damage DNA. 
Other antineoplastic drugs, some antivirals, antibi-
otics, and bioengineered drugs interfere with cell 
growth or proliferation, or with DNA synthesis. In 
some cases, the nonselective actions of these drugs 
disrupt the growth and function of both healthy 
and diseased cells, resulting in toxic side effects 
for treated patients and their offspring. These non-
selective actions can also cause adverse effects in 
healthcare workers who are inadvertently exposed 
to hazardous drugs. However, drugs other than 
those used to treat cancer may have toxic proper-
ties similar to those of the antineoplastic drugs. For 
some other drugs, adverse reproductive effects are 
the primary characteristic of concern for occupa-
tional exposure. NIOSH evaluates the potential of 
proposed additions to the list on the basis of these 
and other characteristics of the drugs.
This document presents criteria and sources of in-
formation for determining whether a drug is haz-
ardous. When a drug has been judged to be hazard-
ous, the various precautions outlined in the Alert 
should be applied when handling that drug. Also 
included is a list of drugs that should be handled 
as hazardous. When applying the criteria for a haz-
ardous drug as outlined above, NIOSH takes the 
following approach.
and Kirk 1988; Naumann and Sargent 1997; Sargent et al. 
2002]. OELs in this range are typically established for po-
tent or toxic drugs in the pharmaceutical industry. Under all 
circumstances, an evaluation of all available data should be 
conducted to protect healthcare workers.
‡In evaluating mutagenicity for potentially hazardous drugs, 
responses from multiple test systems are needed before pre-
cautions can be required for handling such agents. The EPA 
evaluations include the type of cells affected and in vitro ver-
sus in vivo testing [51 Fed Register 34006–34012 (1986)].
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Reproductive and Developmental Toxicity
NIOSH takes into account the dose for animal test-
ing of reproductive and developmental toxicity. If 
adverse effects are observed in animal testing near, 
at, or below the maximum recommended human 
dose (MRHD), NIOSH considers it to be highly rel-
evant. If doses producing an adverse effect are many 
times the MRHD, usually NIOSH does not consider 
them in its evaluation. 
For reproductive and developmental effects, 
NIOSH notes if there was maternal toxicity, in ad-
dition to the dose. Effects on the fetus in the ab-
sence of maternal toxicity are considered relevant. 
Many drugs with an FDA pregnancy category X 
rating meet the criteria for a hazardous drug and 
are listed, but each drug is evaluated individually. 
Similarly, for Category D, these drugs are often 
listed because many meet the criteria for being 
hazardous. Any available human data are consid-
ered significant. In June 2015, the FDA removed 
the pregnancy letter categories (A, B, C, D, and 
X) in prescription drug labeling. The new label-
ing was renamed “Pregnancy,” “Lactation,” and 
“Females and Males of Reproductive Potential” 
[FDA 2015]. The plan for the new labeling is to be 
phased in gradually for drugs approved on or after 
June 2001, but it went into effect immediately for 
drugs and biologic products submitted after June 
2015. Therefore, the pregnancy letter categories are 
still in effect for most of the drugs described in this 
document, for the immediate future.
Carcinogenicity
In addition to dose, for carcinogenicity testing 
NIOSH looks for tumors in more than one species 
and sex. It looks for tumors in multiple organs and 
for tumors that are not rodent-specific. Any avail-
able human data are considered significant.
Genotoxicity
For effects of genotoxicity, NIOSH gives greater 
weight to in vivo testing than in vitro testing. How-
ever, adverse outcomes in several in vitro tests will 
be considered in its evaluation.
Organ Toxicity
For organ toxicity, the low-dose criterion in the 
definition (a daily therapeutic dose of 10 mg/day or 
a dose of 1 mg/kg per day in laboratory animals) is 
used as a benchmark.
Other
Drugs with safe-handling guidelines from the man-
ufacturer are automatically put on the list because 
the manufacturer has determined their properties 
warrant special handling.
A NIOSH internal committee performs an initial 
review of all new FDA drug approvals and new 
warnings on existing drugs for a two-year period. 
Following this review, an expert panel consisting of 
peer reviewers and stakeholders reviews the pro-
posed additions (and deletions, when applicable), 
using information in DrugBank, DailyMed, and 
the DPIs and SDSs. Additionally, a Federal Reg-
ister Notice is published requesting comments on 
the proposed changes to the list. A final review of 
all information is performed by NIOSH, and the 
updated list is published on the NIOSH Hazardous 
Drug Topic Page (http://www.cdc.gov/niosh/top-
ics/hazdrug/) and in the Federal Register.
In addition to using the list of hazardous drugs 
presented here, each organization should create its 
own list of drugs considered to be hazardous, based 
on drugs in its formulary. This document presents 
guidance for making such a facility-specific list (see 
section entitled How to Generate Your Own List of 
Hazardous Drugs). Subsequently, newly purchased 
drugs should be evaluated against the organiza-
tion’s hazardous drug criteria and added to the list 
if they are deemed hazardous. Organizations have 
developed various approaches to identifying and 
classifying hazardous drugs [Chaffee et al. 2010; 
Badry et al. 2013; Kaestli et al. 2013]. Although the 
classification schemes may differ somewhat, the 
drugs listed as hazardous are quite similar.
Individual organizations may not have adequate 
resources for determining their own list of hazard-
ous drugs. If so, the list of hazardous drugs in this 
document will help employers and workers to de-
termine when precautions are needed. However, re-
liance on such a published list is a concern because 
it quickly becomes outdated as new drugs continu-
ally enter the market or listed drugs are removed 
when additional information becomes available. 
NIOSH will update this list periodically by adding 
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drugs that meet its criteria and removing those that 
no longer meet its criteria. This hazardous drug list 
will be posted on the NIOSH website at www.cdc.
gov/niosh/topics/hazdrug/. In addition, drugs that 
have safe-handling guidance from the manufactur-
ers in the DPIs will be posted on this website after 
they are approved by the FDA.
III. How to Generate Your Own List 
of Hazardous Drugs
A. OSHA Hazard Communication
The OSHA hazard communication standard [29 
CFR 1910.1200] requires employers to develop 
a hazard communication program appropriate 
for their unique workplaces. An essential part of 
the program is the identification of all hazardous 
chemicals a worker may encounter in the facility. 
Compliance with the OSHA hazard communica-
tion standard entails developing a list of hazardous 
chemicals (in this case, drugs) as part of the written 
hazardous communication program and inform-
ing workers where that list can be obtained. The 
criteria OSHA uses to identify hazardous chemi-
cals, including hazardous drugs, are provided in 
that standard. Institutions may wish to compare 
their lists to the listing in this document or on the 
NIOSH website.
It is not likely that every healthcare provider or fa-
cility will use all drugs that have received U.S. Food 
and Drug Administration (FDA) approval. Instead, 
compliance requires practice-specific assessments 
for drugs used at any one time by a facility. How-
ever, hazardous drug evaluation is a continual pro-
cess. Each facility must assess each new drug that 
enters its workplace to determine if it needs to be 
included in the Hazard Communication program 
and, when appropriate, reassess its list of hazardous 
drugs when new toxicological data become avail-
able. Toxicological data are often incomplete or 
unavailable for investigational drugs. However, if 
their mechanism of action suggests that there may 
be a concern, it is prudent to handle them as haz-
ardous drugs until adequate information becomes 
available to exclude them.
B. NIOSH List of Hazardous Drugs
The following list (Tables 1–3) contains those drugs 
that NIOSH has reviewed according to the criteria 
in the NIOSH definition of a hazardous drug. The 
list was compiled from the following:
  the 2014 NIOSH update to the list
  the NIOSH 2016 update to the list, for which 
34 drugs were added (including five with the 
manufacturers’ safe-handling warnings).
The OSHA hazard communication standard re-
quires a written program including a list of chemi-
cals that meet the Hazard Communication defi-
nitions for hazardous, labelling, and employee 
training. The mandate applies not only to health-
care professionals who provide direct patient care 
but also to others who support patient care by par-
ticipating in product acquisition, storage, transpor-
tation, housekeeping, and waste disposal. Institu-
tions may want to adopt this list or compare theirs 
with the list on the NIOSH website.
CAUTION: Drugs purchased and used by a fa-
cility may have entered the marketplace after the 
list below was assembled. Therefore, this list may 
not be all-inclusive.
If you use a drug that is not included in the list of 
hazardous drugs, check the available literature to 
see whether the unlisted drug should be treated as 
hazardous. Check the SDS from the manufacturer 
or the DPI. You may also check with other insti-
tutions that might be using the same drug. If any 
of the documents mention carcinogenicity, geno-
toxicity, teratogenicity (Section 13 in the DPI), or 
reproductive or developmental toxicity (Section 8), 
or if the DPI contains safe-handling warnings (Sec-
tion 16), then use the precautions stipulated in the 
Alert. If the drug meets one or more of the crite-
ria for hazardous drugs in the NIOSH definition, 
handle it as hazardous.
The list of hazardous drugs will be updated peri-
odically on the website http://www.cdc.gov/niosh/
topics/hazdrug/.
This list supersedes the lists from 2004 (http://www.
cdc.gov/niosh/docs/2004-165/), 2010, 2012, and 
2014 (http://www.cdc.gov/niosh/docs/2014-138/).
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C. Where to Find Information Related to 
Drug Toxicity
Practice-specific lists of hazardous drugs (usually 
developed by pharmacy or nursing departments) 
should be comprehensive, including all hazard-
ous medications routinely used or very likely to 
be used by a local practice. Here are some of the 
resources that employers can use to evaluate the 
hazard potential of a drug:
  Safety Data Sheets (SDSs, formerly Material 
Safety Data Sheets)
  Product labeling approved by the U.S. FDA 
(DPIs)
  International Agency for Research on Cancer 
(IARC): http://www.iarc.fr 
  DrugBank: http://www.drugbank.ca/
  DailyMed: http://dailymed.nlm.nih.gov/dai-
lymed/
  Special health warnings from drug manufac-
turers, FDA, and other professional groups and 
organizations
  Reports and case studies published in medical 
and other healthcare profession journals
  Evidence-based recommendations from other 
facilities that meet the criteria defining hazard-
ous drugs
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ous Drugs in Healthcare Settings, 2016
NIOSH performs a hazard identification for each 
of the drugs in the following tables, based on its 
criteria as described above. The actual risk to 
healthcare workers depends on toxicity of the 
drugs, how the drugs can enter the body (e.g., der-
mal, inhalation, or ingestion), and how the drugs 
are handled—how they are manipulated, how of-
ten they are handled, and the exposure controls in 
place, such as the type of engineering controls and 
personal protective equipment (PPE) (see Table 5). 
For example,
  Dispensing a single tablet to a patient may pose 
a relatively low risk to the healthcare worker. A 
single pair of gloves may be adequate.
  Repeatedly counting, cutting, or crushing tab-
lets may pose a higher risk for worker exposure 
than dispensing a single tablet and contamina-
tion to the workplace if exposure controls are 
not in place. If a containment device such as a 
BSC (Class II biological safety cabinet) or CACI 
(compounding aseptic containment isolator) is 
not available, then double gloves, a protective 
gown, respiratory protection, and a disposable 
pad to protect the work surface should be used.
  Preparing several intravenous doses of an an-
tineoplastic drug typically poses a higher po-
tential risk to the worker. In addition to double 
gloving and a protective gown, an engineering 
control such as a BSC or CACI, possibly sup-
plemented with a CSTD (closed system drug-
transfer device), is necessary to protect the 
drug, environment, and healthcare worker.
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The drugs in Table 1 meet one or more of the NIOSH criteria for a hazardous drug. In addition to many of 
these drugs being cytotoxic, the majority are hazardous to males or females who are actively trying to conceive, 
women who are pregnant or may become pregnant, and women who are breast feeding, because they may be 
present in breast milk. 
These drugs represent an occupational hazard to healthcare workers and should always be handled with use of 
recommended engineering controls and personal protective equipment (PPE), regardless of their formulation 
(IV [intravenous], SC [subcutaneous], topical, tablet, or capsule). Unopened, intact tablets and capsules may 
not pose the same degree of occupational exposure risk as injectable drugs, which usually require extensive 
preparation. Cutting, crushing, or otherwise manipulating tablets and capsules will increase the risk of exposure 
to workers. The manufacturer’s safe-handling guidance (MSHG) is typically in Section 16 of the DPI. See Table 
5 for safe-handling recommendations. 
Abbreviations and footnotes. AHFS = American Hospital Formulary Service; MRHD = maximum recommend-
ed human dose.
*Drugs in red font were added in 2016.
National Toxicology Program classifications (http://ntp.niehs.nih.gov/pubhealth/roc/index.html): **Known To Be Hu-
man Carcinogens; ***Reasonably Anticipated To Be Human Carcinogens.
†International Agency for Research on Cancer (www.iarc.fr): Group 1, Carcinogenic to Humans; Group 2A, Probably Car-
cinogenic to Humans; Group 2B, Possibly Carcinogenic to Humans.
‡BCG, although classified as a vaccine, is used in the treatment of certain cancers. BCG should be prepared with aseptic tech-
niques. To avoid cross-contamination, parenteral drugs should not be prepared in areas where BCG has been prepared. A 
separate area for the preparation of BCG suspension is recommended. All equipment, supplies, and receptacles in contact 
with BCG should be handled and disposed of as biohazardous. If preparation cannot be performed in a containment de-
vice, then respiratory protection, gloves, and a gown should be worn to avoid inhalation or contact with BCG organisms.
‡‡MSHG was removed in 2015 by the manufacturer.
Table 1. Group 1: Antineoplastic drugs, including those with the 
manufacturer’s safe-handling guidance (MSHG)
Drug AHFS classification MSHG Supplemental information Links
abiraterone 10:00 antineoplastic 
agents
Women who are pregnant 
or may be pregnant should 
not handle without protec-







yes Conjugated monoclonal 
antibody; FDA Pregnancy 
Category D
DailyMed; DrugBank
afatinib* 10:00 antineoplastic 
agents
Special warnings on 
contraception for females 






Drug AHFS classification MSHG Supplemental information Links
altretamine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
amsacrine NA antineoplastic 
agents
yes IARC Group 2B† DrugBank
anastrozole 10:00 antineoplastic 
agents
FDA Pregnancy Category X DailyMed; DrugBank
arsenic trioxide 10:00 antineoplastic 
agents
yes IARC Group 1 carcinogen; 
NTP**; FDA Pregnancy 
Category D
DailyMed; DrugBank
axitinib 10:00 antineoplastic 
agents
Teratogenic, embryotoxic 
and fetotoxic in mice at ex-
posures lower than human 
exposures; FDA Pregnancy 
category D
DailyMed; DrugBank
azacitidine 10:00 antineoplastic 
agents
yes IARC Group 2A carcinogen; 










belinostat 10:00 antineoplastic 
agents
yes May cause teratogenicity 
and/or embryo-fetal lethal-
ity because it is a genotoxic 
drug and targets actively 
dividing cells; FDA Preg-
nancy Category D
DailyMed; DrugBank
bendamustine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
bexarotene 10:00 antineoplastic 
agents
FDA Pregnancy Category X DailyMed; DrugBank
bicalutimide 10:00 antineoplastic 
agents
FDA Pregnancy Category X DailyMed; DrugBank
bleomycin 10:00 antineoplastic 
agents
yes IARC Group 2B; FDA Preg-
nancy Category D
DailyMed; DrugBank
bortezomib 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
Table 1 (Continued). Group 1: Antineoplastic drugs, including those with the 
manufacturer’s safe-handling guidance (MSHG)
(Continued)
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Drug AHFS classification MSHG Supplemental information Links
bosutinib 10:00 antineoplastic 
agents





yes Conjugated monoclonal 
antibody; FDA Pregnancy 
Category D
DailyMed; DrugBank
busulfan 10:00 antineoplastic 
agents
yes IARC Group 1 carcinogen; 
FDA Pregnancy Category D
DailyMed; DrugBank
cabazitaxel 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
cabozantinib 10:00 antineoplastic 
agents
Embryolethal in rats at ex-
posures below the recom-
mended human dose; FDA 
Pregnancy category D
DailyMed; DrugBank
capecitabine 10:00 antineoplastic 
agents
yes Metabolized to 5-fluo-
rouracil; FDA Pregnancy 
Category D
DailyMed; DrugBank
carboplatin 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
carfilzomib 10:00 antineoplastic 
agents
Special warnings on 
contraception while taking 
and 2 weeks post- treat-
ment; FDA Pregnancy 
category D
DailyMed; DrugBank
carmustine 10:00 antineoplastic 
agents
yes IARC Group 2A carcinogen; 
NTP***; FDA Pregnancy 
Category D
DailyMed; DrugBank
chlorambucil 10:00 antineoplastic 
agents
yes IARC Group 1 carcinogen; 
NTP**; FDA Pregnancy 
Category D
DailyMed; DrugBank
cisplatin 10:00 antineoplastic 
agents
yes IARC Group 2A carcinogen; 
NTP***; FDA Pregnancy 
Category D
DailyMed; DrugBank
cladribine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
clofarabine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
Table 1 (Continued) Group 1: Antineoplastic drugs, including those with the 
manufacturer’s safe-handling guidance (MSHG)
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Drug AHFS classification MSHG Supplemental information Links
crizotinib 10:00 antineoplastic 
agents





yes IARC Group 1 carcinogen; 
NTP**; FDA Pregnancy 
Category D
DailyMed; Drugbank
cytarabine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
dabrafenib 10:00 antineoplastic 
agents
Special warnings on 
contraception for females 




dacarbazine 10:00 antineoplastic 
agents
yes NTP***; FDA Pregnancy 
Category C
DailyMed; Drugbank
dactinomycin 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
dasatinib 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; Drugbank
daunorubicin 10:00 antineoplastic 
agents
yes IARC Group 2B, AKA dau-
nomycin; FDA Pregnancy 
Category D
DailyMed; Drugbank
decitabine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; Drugbank
degarelix 10:00 antineoplastic 
agents
-‡‡ FDA Pregnancy Category X DailyMed; Drugbank
docetaxel 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
doxorubicin 10:00 antineoplastic 
agents
yes IARC Group 2A carcinogen; 
NTP***; FDA Pregnancy 
Category D
DailyMed; DrugBank
enzalutamide 10:00 antineoplastic 
agents
Embryo-fetal toxicity in 
mice at exposures that 
were lower than in patients 
receiving the recommend-
ed dose; FDA Pregnancy 
Category X
DailyMed; DrugBank
Table 1 (Continued). Group 1: Antineoplastic drugs, including those with the 
manufacturer’s safe-handling guidance (MSHG)
(Continued)
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Drug AHFS classification MSHG Supplemental information Links
epirubicin 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; Drugbank
eribulin 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
erlotinib 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
estramustine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category X DailyMed; Drugbank
etoposide 10:00 antineoplastic 
agents
yes IARC Group 1 carcinogen; 
FDA Pregnancy Category D
DailyMed; DrugBank
everolimus 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; Drugbank
exemestane 10:00 antineoplastic 
agents
FDA Pregnancy Category X DailyMed; DrugBank
floxuridine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
fludarabine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
fluorouracil 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
flutamide 10:00 antineoplastic 
agents
Indicated only for men; 
FDA Pregnancy Category D
DailyMed; DrugBank
fulvestrant 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
gemcitabine 10:00 antineoplastic 
agents





yes FDA Pregnancy Category D DailyMed; DrugBank 
goserelin 10:00 antineoplastic 
agents
FDA Pregnancy Category X DailyMed; Drugbank
histrelin 10:00 antineoplastic 
agents
Can cause fetal harm when 
administered to a pregnant 
patient, with the possibility 
of spontaneous abortion; 
FDA Pregnancy Category X
DailyMed; DrugBank
Table 1 (Continued). Group 1: Antineoplastic drugs, including those with the 
manufacturer’s safe-handling guidance (MSHG)
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14
Drug AHFS classification MSHG Supplemental information Links
hydroxyurea 10:00 antineoplastic 
agents
yes Special warning on han-
dling bottles and capsules; 
FDA Pregnancy Category D
DailyMed; DrugBank
idarubicin 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
ifosfamide 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
imatinib 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank 
irinotecan 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
ixazomib 10:00 antineoplastic 
agents
yes Male and female patients 
of childbearing potential 
must use effective contra-
ceptive measures during 
and for 3 months following 
treatment
DailyMed; DrugBank
ixabepilone 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
letrozole 10:00 antineoplastic 
agents
FDA Pregnancy Category X DailyMed; DrugBank
leuprolide 10:00 antineoplastic 
agents
yes FDA Pregnancy Category X DailyMed; DrugBank
lomustine 10:00 antineoplastic 
agents
yes IARC Group 2A carcinogen; 







yes NTP***; FDA Pregnancy 
Category D
DailyMed; DrugBank
megestrol 10:00 antineoplastic 
agents
yes Nursing should be dis-
continued if megestrol is 
required; women at risk of 
pregnancy should avoid 
exposure; FDA Pregnancy 
Category X
DailyMed; DrugBank
melphalan 10:00 antineoplastic 
agents
yes IARC Group 1 carcinogen; 




Table 1 (Continued). Group 1: Antineoplastic drugs, including those with the 
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Drug AHFS classification MSHG Supplemental information Links
mercaptopurine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
methotrexate 10:00 antineoplastic 
agents
yes FDA Pregnancy Category X DailyMed; DrugBank
mitomycin 10:00 antineoplastic 
agents
yes IARC Group 2B; FDA Preg-
nancy Category D
DailyMed; DrugBank
mitotane 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
mitoxantrone 10:00 antineoplastic 
agents
yes IARC Group 2B; FDA Preg-
nancy Category D
DailyMed; DrugBank
nelarabine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
nilotinib 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
omacetaxin 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
oxaliplatin 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
paclitaxel 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
panobinostat 10:00 antineoplastic 
agents
yes Special warnings on 
contraception for females 
while taking and 1 month 
post-treatment;
DailyMed; DrugBank
pazopanib 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
pemetrexed 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
pentostatin 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
pertuzumab 10:00 antineoplastic 
agents
Black Box warning on 
embryo-fetal death and 




Table 1 (Continued). Group 1: Antineoplastic drugs, including those with the 
manufacturer’s safe-handling guidance (MSHG)
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Drug AHFS classification MSHG Supplemental information Links
pomalidomide 10:00 antineoplastic 
agents
yes Females of reproductive 
potential must use two 
forms of contraception or 
continuously abstain from 
heterosexual sex dur-
ing and for 4 weeks after 
stopping treatment; FDA 
Pregnancy Category X
DailyMed; DrugBank
ponatinib 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
pralatrexate 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
procarbazine 10:00 antineoplastic 
agents
yes IARC Group 2A carcinogen; 
NTP***; FDA Pregnancy 
Category D
DailyMed; DrugBank
regorafenib 10:00 antineoplastic 
agents
Black Box warning on 
severe and sometimes fatal 
hepatotoxicity; total loss of 
pregnancy at doses lower 
than recommended hu-
man dose; FDA Pregnancy 
Category D
DailyMed; DrugBank
romidepsin 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank 
sorafenib 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
streptozocin 10:00 antineoplastic 
agents
yes IARC Group 2B; NTP***; 
FDA Pregnancy Category D
DailyMed; DrugBank
sunitinib 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
tamoxifen 10:00 antineoplastic 
agents
IARC Group 1 carcinogen; 
NTP**; FDA Pregnancy 
Category D
DailyMed; DrugBank
temozolomide 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
temsirolimus 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
(Continued)
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Drug AHFS classification MSHG Supplemental information Links
teniposide 10:00 antineoplastic 
agents
yes IARC Group 2A carcinogen; 
FDA Pregnancy Category D
DailyMed; DrugBank
thioguanine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
thiotepa 10:00 antineoplastic 
agents
yes IARC Group 1 carcinogen; 
NTP**; FDA Pregnancy 
Category D
DailyMed; DrugBank
topotecan 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
toremifene 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
trametinib 10:00 antineoplastic 
agents
Embryotoxic and abortifa-
cient at doses less than rec-
ommended human dose; 







yes Embryo-fetal lethality and 
embryo-fetal toxicity at 
doses lower than or similar 




triptorelin 10:00 antineoplastic 
agents
FDA Pregnancy Category X DailyMed; DrugBank
valrubicin 10:00 antineoplastic 
agents
yes FDA Pregnancy Category C DailyMed; DrugBank
vandetanib 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
vemurafenib 10:00 antineoplastic 
agents
FDA Pregnancy Category D DailyMed; DrugBank
vinblastine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
vincristine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
vinorelbine 10:00 antineoplastic 
agents
yes FDA Pregnancy Category D DailyMed; DrugBank
(Continued)
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Drug AHFS classification MSHG Supplemental information Links
vismodegib 10:00 antineoplastic 
agents
Black Box warning on 
embryo-fetal death or 
severe birth defects; rec-
ommend effective contra-
ception for females during 
therapy and for 7 months 
after treatment; present in 
semen; no sperm donation 
during and 3 months post-
treatment; FDA Pregnancy 
Category D
DailyMed; DrugBank
vorinostat 10:00 antineoplastic 
agents
yes Adverse embryo-fetal 
effects at less than the rec-
ommended human dose; 
FDA Pregnancy Category D
DailyMed; DrugBank
ziv-aflibercept 10:00 antineoplastic 
agents
Embryotoxic and terato-
genic in rabbits at expo-
sure levels lower than 
human exposures at the 
recommended dose, with 
increased incidences of ex-
ternal, visceral, and skeletal 
fetal malformations; FDA 
Pregnancy Category C
DailyMed; DrugBank
Table 1 (Continued). Group 1: Antineoplastic drugs, including those with the 
manufacturer’s safe-handling guidance (MSHG)
19
The drugs in Table 2 meet one or more of the NIOSH criteria for a hazardous drug. Some of these drugs 
may represent an occupational hazard to males or females who are actively trying to conceive, women who 
are pregnant or may become pregnant, and women who are breast feeding, because they may be present in 
breast milk.
Unopened, intact tablets and capsules may not pose the same degree of occupational exposure risk as in-
jectable drugs, which usually require extensive preparation. Cutting, crushing, or otherwise manipulating 
tablets and capsules will increase the risk of exposure to workers. The manufacturer’s safe-handling guidance 
(MSHG) is typically in Section 16 of the DPI. See Table 5 for safe-handling recommendations. 
Abbreviations and footnotes. AHFS = American Hospital Formulary Service; MRHD = maximum recom-
mended human dose.
*Drugs in blue font meet one or more criteria for a hazardous drug and also pose a potential reproductive hazard.
National Toxicology Program (http://ntp.niehs.nih.gov/pubhealth/roc/index.html): **Known To Be Human Car-
cinogens; ***Reasonably Anticipated To Be Human Carcinogens.
†International Agency for Research on Cancer (www.iarc.fr): Group 1, Carcinogenic to Humans; Group 2A, Probably 
Carcinogenic to Humans; Group 2B, Possibly Carcinogenic to Humans.
‡Drugs in red font were added in 2016.
Table 2. Group 2: Non-antineoplastic drugs that meet one or more of the NIOSH criteria for a 
hazardous drug, including those with the manufacturer’s safe-handling guidance (MSHG)
Drug AHFS classification MSHG Supplemental information Links
abacavir 8:18.08.20 nucleoside 
and reverse transcrip-
tase inhibitors
FDA Pregnancy Category C; 
malignant tumors observed 
in male and female mice and 
rats; genotoxic in in vivo mi-
cronucleus test
DailyMed; DrugBank
alefacept 84:92 skin and mucous 
membrane agents, 
miscellaneous
Increased frequency of malig-
nancies observed in treated 





Black Box warning for aplastic 
anemia; congenital malforma-
tions in offspring of mothers 
who took drug; rapid transpla-
cental passage; FDA Pregnan-
cy Category D*
DailyMed; DrugBank
apomorphine 28:36.20.08 non-ergot- 
derivative dopamine 
receptor agonists
FDA Pregnancy Category C; 





Drug AHFS classification MSHG Supplemental information Links
azathioprine 92:44 immunosup-
pressants 
yes IARC Group 1 carcinogen†; 





IARC Group 2A carcinogen; 
NTP***; FDA Pregnancy 
Category C
DailyMed; DrugBank 
cidofovir 8:18:32 nucleosides 
and nucleotides
yes FDA Pregnancy Category C DailyMed; DrugBank
cyclosporine 92:44 immunosup-
pressive agents
IARC Group 1 carcinogen; 
NTP**; FDA Pregnancy 
Category C
DailyMed; DrugBank 
deferiprone 64:00 heavy metal 
antagonists
Genotoxic in vitro and in vivo; 
FDA Pregnancy Category D
DailyMed; DrugBank 
dexrazoxane 92:56 protective 
agents
yes FDA Pregnancy Category 
C; secondary malignancies 
observed in patients treated 
long term with Razoxane (a 
racemic mixture containing 
dexrazoxane); genotoxic in 
vitro and in vivo; in laboratory 
studies, testicular atrophy 
observed at or below the hu-
man dose
DailyMed; DrugBank
diethylstilbestrol NA IARC Group 1 carcinogen; 





Black Box warning for tera-
togenicity; FDA Pregnancy 
Category D; tumors seen in 
laboratory studies at doses 
below MRHD
DailyMed; DrugBank
entecavir 8:18:32 nucleosides 
and nucleotides
FDA Pregnancy Category C DailyMed; DrugBank
(Continued)
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Drug AHFS classification MSHG Supplemental information Links
estradiol 68:16:04 estrogens Black Box warning for malig-
nant neoplasms; increased risk 
of endometrial cancer, breast 
cancer, and ovarian cancer; in 
laboratory studies, increased 
frequency of carcinomas of 
the breast, uterus, cervix, va-
gina, testis, and liver; present 





68:12 contraceptives IARC Group 1 carcinogen; 





68:16:04 estrogens Black Box warning for endo-
metrial cancer and cardiovas-
cular risks; long-term use in 
women and laboratory studies 
increases frequency of several 
cancers; NTP**; FDA Pregnan-
cy Category X
DailyMed; DrugBank 
estrogens, esterified 68:16:04 estrogens Black Box warning for endo-
metrial cancer and cardio-
vascular risks; NTP**; FDA 
Pregnancy Category X
DailyMed; DrugBank
estropipate 68:16:04 estrogens Black Box warning for endo-
metrial carcinoma in post-
menopausal women and 
use during pregnancy; FDA 
Pregnancy Category X
DailyMed; DrugBank
fingolimod 92:20 biologic re-
sponse modifiers
FDA Pregnancy Category C; in 
laboratory studies, increased 
malformations and embryo-
fetal deaths at less than 
the recommended human 
dose; malignant lymphomas 
observed in male and female 
mice
DailyMed; DrugBank
fluoxymesterone 68:08 androgens Tumors in mice and rats and 
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Drug AHFS classification MSHG Supplemental information Links
fosphenytoin 28:12.12 hydantoins Metabolized to phenytoin; 
FDA Pregnancy Category D
DailyMed; DrugBank
ganciclovir 8:18:32 nucleosides 
and nucleotides




Teratogenic in laboratory 
studies at 1/10 human dose 
(HD); marked postnatal surviv-
al at 1/100 HD; FDA Pregnancy 
Category X; severe liver injury 
reported in patients; carcino-
genicity observed at doses 
below HD
DailyMed; DrugBank
lenalidomide 92:20 biologic re-
sponse modulators
yes Analog of thalidomide; FDA 
Black Box warnings for limb 
abnormalities; Pregnancy Cat-
egory X; in laboratory studies, 
caused thalidomide-type limb 






FDA Pregnancy Category C; 
Black Box warning for thyroid 
C-cell tumors, with supporting 
evidence in laboratory stud-
ies; also in laboratory studies, 





68:32 progestins yes IARC Group 2B; FDA Pregnan-
cy Category X
DailyMed; DrugBank
methimazole‡ 68:36:08 antithyroid 
agents
Appears in human breast milk; 
FDA Pregnancy Category D
DailyMed; DrugBank
mipomersen 24:06:92 antilipemic 
agents, miscellaneous
Black Box warning on hepa-
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Black Box warning for em-
bryo fetal toxicity, malignan-
cies, and serious infections; 
increased risk of first-trimester 
pregnancy loss and increased 
risk of congenital malforma-
tions; FDA Pregnancy Cat-
egory D; Special warning: 
Tablets should not be crushed 
and capsules should not be 
opened or crushed. Avoid in-
halation or direct contact with 
skin or mucous membranes 
of the powder contained in 
capsules and oral suspension 
(before or after constitution). 
If such contact occurs, wash 
thoroughly with soap and 
water; rinse eyes with plain 
water.
DailyMed; DrugBank
mycophenolic acid 92:44 immunosup-
pressive agents
Black Box warning for first 
trimester pregnancy loss and 
an increased risk of congenital 
malformations; FDA Preg-
nancy Category D; Black Box 
warning for lymphomas and 
other malignancies; genotoxic 





FDA Pregnancy Category B; in 
laboratory studies, hepatocel-
lular adenomas and carci-
nomas at doses lower than 
human dose
DailyMed; DrugBank
ospemifene 68:16:12 estrogen 
agonists-antagonists
Black Box warning on in-
creased risk of endometrial 
cancer in certain populations; 
risk of adverse outcomes dur-





Tumors observed in laborato-
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palifermin 84:16 cell stimulants 
and proliferants
FDA Pregnancy Category C; 
potential for stimulation of 
tumor growth
DailyMed; DrugBank
paliperidone 28:16:08:04 atypical 
antipsychotics
Metabolite of risperidone; ex-
creted in human breast milk; 





IARC Group 2B; FDA 
Pregnancy Category C
DailyMed; DrugBank
phenytoin 28:12.12 hydantoins IARC Group 2B; NTP***; FDA 
Pregnancy Category D
DailyMed; DrugBank
pipobroman NA FDA Pregnancy Category D DrugBank
progesterone 68:32 progestins IARC Group 2B; NTP*** DailyMed; DrugBank
progestins 68:12 contraceptives FDA Pregnancy Category X DailyMed
propylthiouracil 68:36.08 antithyroid 
agents
IARC Group 2B; NTP***; FDA 
Pregnancy Category D
DailyMed; DrugBank
raloxifene 68:16:12 estrogen 
agonists-antagonists
Abortion and developmental 
abnormalities seen at low 
doses in laboratory studies; 
evidence of tumors at low 
doses in laboratory studies; 
FDA Pregnancy Category X
DailyMed; DrugBank 
rasagiline 28:36 antiparkinsonian 
agents
FDA Pregnancy Category C DailyMed; DrugBank
risperidone 28:16:08:04 atypical 
anti-psychotics
Evidence of tumors at low 
doses in laboratory studies; 
may be prolactin-mediated; 




AKA rapamycin; increased risk 
of lymphomas and other ma-
lignancies; embryotoxic and 
fetotoxic at 0.2 human dose; 
FDA Pregnancy Category C
DailyMed; DrugBank
(Continued)
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FDA Pregnancy Category C; 
Black Box warning for tumoro-




Increased risk of lymphomas 
and other malignancies; 
reproductive effects seen in 
laboratory studies below the 
MRHD; excreted in breast milk; 




Black Box warning on severe 
hepatotoxicity and terato-
genicity, including major 
birth defects; FDA Pregnancy 
Category X
DailyMed; DrugBank
thalidomide 92:20 biologic re-
sponse modulators
yes FDA Pregnancy Category X DailyMed; DrugBank
tofacitinib 92:36 disease modi-
fying antirheumatic 
drugs
Black Box warning for lympho-
ma and other malignancies; 
FDA Pregnancy Category C
DailyMed; DrugBank
uracil mustard NA yes FDA Pregnancy Category D DrugBank
valganciclovir 8:18:32 nucleosides 
and nucleotides
yes FDA Pregnancy Category C DailyMed; DrugBank
zidovudine 8:18:08 antiretroviral 
agents
IARC Group 2B; FDA 
Pregnancy Category C
DailyMed; DrugBank
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The drugs in Table 3 primarily meet the NIOSH criteria for reproductive hazards. They represent a potential 
occupational hazard to males or females who are actively trying to conceive, women who are pregnant or may 
become pregnant, and women who are breast feeding, as they may be present in breast milk. Unopened, intact 
tablets and capsules may not pose the same degree of occupational risk as injectable drugs that usually require 
extensive preparation. Cutting, crushing, or otherwise manipulating tablets and capsules will increase the risk 
of exposure to workers. The manufacturer’s safe-handling guidance (MSHG) is typically in Section 16 of the 
DPI. See Table 5 for safe handling recommendations. 
*Drugs in red font were added in 2016.
Table 3. Group 3: Non-antineoplastic drugs that primarily have adverse reproductive effects
Drug AHFS classification Supplemental information Links
acitretin 88:04 vitamin A Black Box warning on adverse 
reproductive effects; FDA Preg-
nancy Category X
DailyMed; DrugBank
alitretinoin 84:92 skin and mucous 
membrane agents, 
miscellaneous
FDA Pregnancy Category D DailyMed; DrugBank
ambrisentan 24:12:92 vasodilating 
agents, miscellaneous
Black Box warning on adverse 
reproductive effects; reduced 
sperm counts in patients; FDA 
Pregnancy Category X
DailyMed; DrugBank
bosentan 24:12:92 vasodilating 
agents, miscellaneous 
Black Box warning on adverse 






Inhibition of conception and 
embryo fetal effects at doses be-
low recommended human dose; 





FDA Pregnancy Category X DailyMed; DrugBank
choriogonadotropin 68:18 gonadotropins FDA Pregnancy Category X; may 
cause fetal harm when adminis-
tered to a pregnant woman
DailyMed; DrugBank
clomiphene* 68:16:12 estrogen 
agonist-antagonists
FDA Pregnancy Category X DailyMed; DrugBank
clonazepam 28:12:08 benzodiaz-
epines
Increased risk of congenital 
abnormalities when taken in 





Drug AHFS classification Supplemental information Links
colchicine 92:16 anti-gout agents FDA Pregnancy Category C; 
published animal reproduc-
tion and development studies 
indicate it causes embryofetal 
toxicity, teratogenicity, and al-
tered postnatal development at 
exposures within or above the 
clinical therapeutic range
DailyMed; DrugBank
dinoprostone 76:00 oxytocics Hazardous only for women in 
late pregnancy; FDA Pregnancy 
Category C
DailyMed; DrugBank 
dronedarone 24:04:04 antiarrythmics Teratogenic in laboratory stud-
ies at ½ MRHD; FDA Pregnancy 
Category X
DailyMed; DrugBank 
dutasteride 92:08 5-alpha reductase 
inhibitors
Women warned not to handle; 




Fetal malformations, fetal 
growth retardation, embryo-
lethality, and reduced body 
weights observed in animal 
studies; excreted in human 





76:00 oxytocics Use is contraindicated during 
pregnancy because of its utero-




finasteride 92:08 5-alpha reductase 
inhibitors
Women should not handle 
crushed or broken finasteride 
tablets when they are pregnant 
or may potentially be pregnant, 
due to potential risk to a male 
fetus; FDA Pregnancy Category X
DailyMed; DrugBank 
fluconazole 8:18.08 azoles FDA Pregnancy Category C; 
case reports describe congeni-
tal anomalies in infants exposed 
in utero to maternal fluconazole 
(400–800 mg/ day) during 
most or all of the first trimester, 
similar to those seen in animal 
studies
DailyMed; DrugBank
Table 3 (Continued). Group 3: Non-antineoplastic drugs that 
primarily have adverse reproductive effects
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Drug AHFS classification Supplemental information Links
ganirelix 92:40 gonadotropin- 
releasing hormone 
antagonists
FDA Pregnancy Category X DailyMed; DrugBank
gonadotropin, chorionic 68:18 gonadotropins Defects of forelimbs and central 
nervous system and alterations 
in sex ratio have been reported 
in laboratory studies; FDA Preg-
nancy Category C
DailyMed; DrugBank
icatibant 92:32 complement 
inhibitors
FDA Pregnancy Category C; 
in laboratory studies, prema-
ture birth and abortion rates 
increased at a dose that was 
less than 1/40th the MRHD, 
and delayed parturition and 
fetal death occurred at 0.5 and 
2-fold, respectively, the MRHD
DailyMed; DrugBank
lomitapide 24:06:92 antilipemic 
agents, miscellaneous
FDA Pregnancy Category X DailyMed; DrugBank
macitentan 48:48 vasodilating 
agents
Black Box warning for embryo-
fetal toxicity; special warnings 
on contraception for females 
while taking and 1 month 
post-treatment; FDA Pregnancy 
Category X
DailyMed; DrugBank
mentropins 68:18 gonadotropins FDA Pregnancy Category X DrugBank
methyltestosterone 68:08 androgens FDA Pregnancy Category X DailyMed; DrugBank
mifepristone 76:00 oxytocics When given to pregnant 
women, results in termination 
of pregnancy; FDA Pregnancy 
Category X
DailyMed; DrugBank
misoprostol 56:28.28 prostaglandins FDA Pregnancy Category X DailyMed; DrugBank
nafarelin 68:18 gonadotropins Note: Given only as nasal spray; 
no potential for occupational 
exposure; FDA Pregnancy 
Category X
DailyMed; DrugBank
oxytocin 76:00 oxytocics Hazardous only for women in 




Table 3 (Continued). Group 3: Non-antineoplastic drugs that 
primarily have adverse reproductive effects
29
Drug AHFS classification Supplemental information Links
pamidronate 92:24 bone resorption 
inhibitors 
Embryo-fetal toxicities at doses 
below the recommended hu-
man dose; FDA Pregnancy 
Category D
DailyMed; DrugBank
paroxetine 28:16:04:20 selective 
serotonin uptake inhibi-
tors
Increased risk of congenital 
abnormalities when taken in 
first trimester; complications 
in pregnancy when taken in 
third trimester; FDA Pregnancy 
Category D
DailyMed; DrugBank
pasireotide 68:29:04 somostatin 
agonists
Increased implantation loss 
and decreased viable fetuses, 
corpora lutea, and implantation 
sites at doses less than the hu-





NA Severe teratogenic effects in 
laboratory studies in dogs; sup-
plied in ampule, which can lead 
to occupational exposure; FDA 
Pregnancy Category C
DailyMed
peginesatide 20:16 hematopoietic 
agents
Adverse embryo-fetal effects, 
including reduced fetal weight, 
increased resorption, embryo-
fetal lethality, and cleft palate, 
observed in doses below the 
recommended human dose; 
FDA Pregnancy Category C
DailyMed; DrugBank
plerixafor 20:16 hematopoietic 
agents
Teratogenic in laboratory stud-
ies; FDA Pregnancy Category D
DailyMed; DrugBank
ribavirin 8:18:32 nucleosides and 
nucleotides
Teratogenic and embryo-
toxic effects in several labora-
tory studies; contraindicated in 
women who are pregnant and 
in the male partners of women 
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Drug AHFS classification Supplemental information Links
riociguat 48:48 vasodilating 
agents
Exclude pregnancy before the 
start of treatment, monthly 
during treatment, and 1 month 
after stopping treatment; FDA 
Pregnancy Category X
DailyMed; DrugBank 
telavancin 8:12:28 glycopeptides Black Box warning for potential 
risk to fetus and adverse repro-
ductive outcomes; reduced fetal 
weights and increased rates of 
digit and limb malformations in 
three species at clinical doses; 




Increased risk of congenital 
malformations associated 
with treatment during the first 
trimester of pregnancy; FDA 
Pregnancy Category X
DailyMed; DrugBank
testosterone 68:08 androgens Children should avoid contact 
with unwashed or unclothed 





FDA Pregnancy Category D DailyMed; DrugBank
tretinoin 84:16 cell stimulants 
and proliferants
Black Box warning for severe 
birth defects; Special FDA distri-
bution system; FDA Pregnancy 
Category X
DailyMed; DrugBank
ulipristal 68:12 contraceptives FDA Pregnancy Category X DailyMed
valproate/valproic acid 28:12:92 anticonvul-
sants, miscellaneous
Black Box warning for terato-
genicity; congenital malforma-
tions, including neural tube 
defects; teratogenic in multiple 






Malformations seen in labora-
tory studies below the MRHD; 
FDA Pregnancy Category C
DailyMed; Drugbank
voriconazole 8:14.08 azoles FDA Pregnancy Category D DailyMed; DrugBank
(Continued)
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Drug AHFS classification Supplemental information Links
warfarin 20:12.04.08 coumarin 
derivatives
FDA Pregnancy Category D DailyMed; DrugBank
ziprasidone 28:16:08:04 atypical 
antipsychotics
Developmental toxicity, includ-
ing possible teratogenic effects 
at doses similar to human thera-
peutic doses; an increase in the 
number of pups born dead and 
a decrease in postnatal survival 
at less than MRHD; FDA Preg-
nancy Category C*
DailyMed; DrugBank 
zoledronic acid 92:24 bone resorption 
inhibitors
Number of stillbirths increased 
and survival of neonates de-
creased in laboratory studies 





Teratogenic in multiple miscel-
laneous animal species; FDA 
Pregnancy Category D
DailyMed; DrugBank 
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Table 4 would list drugs that were deleted from the 2014 NIOSH hazardous drug list for the 2016 update; how-
ever, there are no deletions to report.
Table 5. Personal protective equipment and engineering controls for 
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no (single glove 
can be used)













Administration no (single glove 
can be used)




Table 5 provides general guidance for some of the possible scenarios that may be encountered in healthcare 
settings where hazardous drugs are handled, but it cannot cover all possible situations. 
Abbreviations and footnotes. BSC = Class II biological safety cabinet; CACI = compounding aseptic containment 
isolator; CSTD = closed system drug-transfer device; HIPEC = hyperthermic intraperitoneal chemotherapy.
*This guidance applies to the drugs in Tables 1–3. For more detailed information on safe-handling practices, see the refer-
ence list [NIOSH 2004; ASHP 2006; ONS 2011; USP 2016; OSHA 2016].
†For nonsterile preparations, a ventilated engineering control such as a fume hood or Class I BSC or a HEPA-filtered enclo-
sure (such as a powder hood) is sufficient if the control device exhaust is HEPA filtered or appropriately exhausted to the 
outside of the building. It is recommended that these activities be carried out in a control device, but it is recognized that 
under some circumstances, it is not possible. If the activity is performed in a ventilated engineering control that is used for 
sterile intravenous preparations, a thorough cleaning is required following the activity.
‡Required if patient may resist (infant, unruly patient, patient pre-disposed to spitting out, patient who has difficulty swal-
lowing, veterinary patient) or if the formulation is hard to swallow.
§Sterile gloves are required for aseptic drug preparation in BSC or CACI.

















































































solution from a 
vial or am-
poule
Compounding yes§ yes no no yes, BSC or 





yes yes yes; if liquid 
that could 
splash‡
no N/A; CSTD 
required per 
USP 800 if 
the dosage 
form allows
Table 5 (Continued). Personal protective equipment and engineering controls for 
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Table 5 (Continued). Personal protective equipment and engineering controls for 
























yes, BSC or 
























yes yes yes yes yes, when 
applicable






























Spills Cleaning yes yes yes yes N/A

To receive NIOSH documents or more information about occupational 




or visit the NIOSH Website at www.cdc.gov/niosh.
For a monthly update on news at NIOSH, subscribe to NIOSH eNews by 
visiting www.cdc.gov/niosh/eNews.
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